- Conditions
- Cancer of the Prostate
- Interventions
- BHR-200 (0.36% transdermal 17β-estradiol gel), Placebo
- Drug
- Lead sponsor
- BHR Pharma, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Aventura, Florida • Daytona Beach, Florida + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 3,920
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- Sonablate HIFU device
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 40 Years to 85 Years · Male only
- Enrollment
- 100 participants
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
- Interventions
- Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin, Irinotecan (drug), Topotecan
- Drug
- Lead sponsor
- Phanes Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 11 more
- Conditions
- Prostate Cancer
- Interventions
- 64Cu-SAR-bisPSMA
- Diagnostic Test
- Lead sponsor
- Luke Nordquist, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Prostate Carcinoma
- Interventions
- Biopsy of Prostate, Gallium Ga 68 Gozetotide, Transrectal Ultrasonography Guided Biopsy
- Procedure · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- Androgen Deprivation Therapy (ADT), Focal prostate ablation (focal therapy)
- Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer(NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Interventions
- Tisotumab Vedotin (HuMax-TF-ADC)
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 8
- States / cities
- Orange, California • New Haven, Connecticut • Miami, Florida + 5 more
- Conditions
- Prostate Cancer
- Interventions
- Tazverik
- Drug
- Lead sponsor
- Edwin Posadas, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 1,937 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Prostate Cancer Patients
- Interventions
- 11C-Acetate
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Leuvectin
- Biological
- Lead sponsor
- Vical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Cleveland, Ohio
- Conditions
- Metastatic Hormone Sensitive Prostate Cancer
- Interventions
- Enzalutamide, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 34
- States / cities
- Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 30 more
- Conditions
- Prostate Cancer
- Interventions
- Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
- Drug
- Lead sponsor
- Carolina Research Professionals, LLC
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Towson, Maryland • Omaha, Nebraska • Syracuse, New York + 2 more
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Interventions
- LY3410738, Gemcitabine, Cisplatin, Durvalumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
- Conditions
- Prostate Cancer
- Interventions
- Cu-NU101
- Drug
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Newport Beach, California • St Louis, Missouri
- Conditions
- Prostate Cancer, Erectile Dysfunction
- Interventions
- questionnaires, three in-person sessions, monthly phone calls, Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED), Enhanced Monitoring and Education (EME)
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
- Interventions
- Abiraterone Acetate, Prednisone\Prednisolone
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 154 more
- Conditions
- Prostate Cancer
- Interventions
- Decipher
- Other
- Lead sponsor
- GenomeDx Biosciences Corp
- Industry
- Eligibility
- Male only
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 19
- States / cities
- Anchorage, Alaska • Los Angeles, California • Aurora, Colorado + 15 more
- Conditions
- Prostate Cancer
- Interventions
- FTLEAD, Ultra-Short-Term Androgen Deprivation Therapy with Relugolix, HypoLEAD, ADT Standard of Care
- Radiation · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 35 Years to 85 Years · Male only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
- Interventions
- NUV-868, Olaparib, Enzalutamide
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more
- Conditions
- Castration-resistant Prostate Cancer, CRPC
- Interventions
- Seviteronel: given orally once daily in 28 day cycles
- Drug
- Lead sponsor
- Innocrin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 19
- States / cities
- Homewood, Alabama • Tampa, Florida • Jeffersonville, Indiana + 16 more
- Conditions
- Prostatic Neoplasms, Metastatic Hormone-Sensitive Prostate Cancer
- Interventions
- Darolutamide, Abiraterone acetate, Enzalutamide, Apalutamide
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Behavioral Dietary Intervention, Counseling, Educational Intervention, Exercise Intervention, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment, Triptorelin Pamoate
- Behavioral · Other · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Male only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Radiation Therapy, Casodex and Zoladex (or Lupron)
- Drug · Radiation
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 85 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas